The board is considering studying eight name brand prescription drugs that treat a variety of diseases, including diabetes, HIV, and attention-deficit/hyperactivity disorder (ADHD).
Bill would allow the board to implement upper payment limits for prescription drug purchases and payer reimbursements if the state finds that certain drugs are ‘unaffordable.’
The Prescription Drug Affordability Board is working with a large list of ‘eligible’ prescription drugs that meet certain statutory or regulatory metrics that could indicate a drug is hard for Marylanders to afford.